From research and development, sourcing and manufacturing, to access and delivery, alliances and collaborations are at the heart of the Novartis Malaria Initiative.
The Novartis Malaria Initiative journey began in 1994 with a joint venture between Novartis and Chinese partners (Academy of Military Medical Sciences, The CITIC Group and Kunming Pharmaceutical Corporation) to develop, test and manufacture an antimalarial treatment – the first collaboration of its kind in Chinese history. Later, other critical partnerships in China have included alliances with suppliers to grow Artemisia annua to supply the raw ingredient needed for our artemisinin-based combination therapy (ACT).
In a landmark agreement with the World Health Organization in 2001, Novartis committed to making its ACT available without profit to the public sector of malaria-endemic countries. Although the agreement expired in May 2011, Novartis continues to provide treatments on the same terms as before to the public sector of malaria-endemic countries.
In 2009, Novartis and Medicines for Malaria Venture launched a new pediatric formulation, becoming the first dispersible fixed-dose ACT specially tailored to infants and children.
Since 2010 we have been participating in an initiative called the “Affordable Medicines Facility Malaria” (now called “co-payment mechanism”) which is a Global Fund financing program to expand access to ACTs for patients at a subsidized price in both the private and public sectors.
The Novartis Malaria Initiative also counts ongoing research collaborations with public and private organizations worldwide. We work in close cooperation with scientists across the Novartis commercial research network as well.
No part of society alone can solve challenges of that magnitude and achieving a sustainable health future cannot happen without more public-private partnerships.